title: Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
abstract: OBJECTIVE
  To describe the clinical and fluorescein angiographic appearance of cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS).
  
  
  METHODS
  We retrospectively examined the clinical and photographic records of four patients with AIDS and cytomegalovirus retinitis who developed cystoid macular edema.
  
  
  RESULTS
  Seven eyes of four patients with AIDS and cytomegalovirus retinitis experienced decreased vision associated with cystoid macular edema. Vitreous inflammation was mild in each patient. In all eyes, the retinitis involved zone 1, and in all but one eye, the cytomegalovirus retinitis was inactive. In one eye, the cystoid macular edema was worsened by formation of a dense juxtafoveal epiretinal membrane.
  
  
  CONCLUSIONS
  Although infrequently recognized, cystoid macular edema can cause visual loss in patients with AIDS and cytomegalovirus retinitis. Fluorescein angiography should be considered in any patient with cytomegalovirus retinitis and unexplained visual loss.
authors.affiliation: The Francis I. Proctor Foundation, Department of Ophthalmology, University of California, San Francisco, School of Medicine, 94143-0944, USA.
authors.forename: B E
authors.initials: BE
authors.lastname: Silverstein
authors.forename: J H
authors.initials: JH
authors.lastname: Smith
authors.forename: S O
authors.initials: SO
authors.lastname: Sykes
authors.forename: M R
authors.initials: MR
authors.lastname: Jones
authors.forename: D
authors.initials: D
authors.lastname: Schwartz
authors.forename: E T
authors.initials: ET
authors.lastname: Cunningham
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D000086:Acetazolamide / Q000627:therapeutic use; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D017726:Cytomegalovirus Retinitis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D005451:Fluorescein Angiography; D017245:Foscarnet / Q000627:therapeutic use; D005654:Fundus Oculi; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D020911:Ketorolac Tromethamine; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008297:Male; D012189:Retrospective Studies; D014046:Tolmetin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014325:Tromethamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014792:Visual Acuity
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000998:Antiviral Agents; D002257:Carbonic Anhydrase Inhibitors; D014325:Tromethamine; D017245:Foscarnet; D020911:Ketorolac Tromethamine; D014046:Tolmetin; D000086:Acetazolamide; D015774:Ganciclovir